Chronic Total Occlusion and Triglyceride-Glucose Index

February 28, 2026 updated by: Rukiye Gonen Ozdemir, Kırıkkale University

The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease

We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study population will consist of adult patients (≥18 years of age) undergoing coronary angiography, who will be divided into two groups according to the presence or absence of chronic total occlusion (CTO).

Description

Inclusion Criteria:

  • Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals

Exclusion Criteria:

  • Patients <18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI >30 kg/m²), inaccessible patient records

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Non CTO
CTO (chronic total occlusion)
Diagnostic test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.
As no previous studies have demonstrated the predictive value of the TyG index for chronic total occlusion (CTO), the present investigation provides a novel contribution to the literature. We hypothesize that the triglyceride-glucose (TyG) index will be significantly higher in patients with chronic total occlusion (CTO) compared to those without CTO.
CTO
CTO (chronic total occlusion)
Diagnostic test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.
As no previous studies have demonstrated the predictive value of the TyG index for chronic total occlusion (CTO), the present investigation provides a novel contribution to the literature. We hypothesize that the triglyceride-glucose (TyG) index will be significantly higher in patients with chronic total occlusion (CTO) compared to those without CTO.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples.
Time Frame: 1 Year
1 Year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kırıkkale University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 15, 2026

Primary Completion (Estimated)

July 15, 2026

Study Completion (Estimated)

September 15, 2026

Study Registration Dates

First Submitted

February 28, 2026

First Submitted That Met QC Criteria

February 28, 2026

First Posted (Actual)

March 5, 2026

Study Record Updates

Last Update Posted (Actual)

March 5, 2026

Last Update Submitted That Met QC Criteria

February 28, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026.02.17

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CAD - Coronary Artery Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe